Biogen acquires TJ Biopharma's felzartamab rights in China for $850M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
April 20, 2026 7:30 AM EDTWith this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one ownerAdvancing felzartamab a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions in the Greater China Region presents an important opportunity in a key global marketAgreement builds on TJ Biopharma's development success of felzartamab in China and productive clinical collaboration in Biogen-led Phase 3 trials for IgAN and PMN since April... More
